Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    15939524 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Terminated A Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before Cystectomy
Conditions: Bladder Carcinoma;   Infiltrative Bladder Carcinoma;   Cystectomy
Intervention: Drug: LAPATINIB

Indicates status has not been verified in more than two years